

Docket No.: LEN 102

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

ATTORNEYS AT LAW

NEUSTADT P.C.

OBLON SPIVAK **McClelland** MAIER

JAMES J. KELLY, PH.D. (703) 413-3000 JKELLY@OBLON.COM

RE: Application Serial No.: 09/709,045

M. Rigdon LENTZ Applicants: Filing Date: November 10, 2000

For: METHOD AND SYSTEM TO REMOVE CYTOKIN

INHIBITOR IN PATIENTS

Group Art Unit: 1647 Examiner: L. SPECTOR

SIR:

Attached hereto for filing are the following papers:

Amendment under C.F.R. §1.116 Expedited Prosecution; 37 C.F.R. 41.202 Suggestion of an Interference; & Copy of U.S. 6,379,708

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

James J. Kelly, Ph.D

Registration No. 41,504

Customer Number

22850

(703) 413-3000 (phone) (703) 413-2220 (fax)

MAY 0 6 2005 SEE

DOCKET NO: LEN 102

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

M. RIGDON LENTZ : EXAMINER: L. SPECTOR

SERIAL NO: 09/709,045

FILED: NOVEMBER 10, 2000 : GROUP ART UNIT: 1647

FOR: METHOD AND SYSTEM TO REMOVE CYTOKINE INHIBITOR IN

PATIENTS

AMENDMENT UNDER C.F.R. 1.116 <u>EXPEDITED PROSECUTION</u>

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Office Action dated January 6, 2005, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

A discussion of the **Support for the Amendments** begins on page 5 of this paper.

Remarks begin on page 8 of this paper.